FindTrial
Sign In

COMPARING CHANGE IN OCCULAR RIGIDTY IN BOTH GLAUCOMA AND NON GLAUCOMA PATIENTS AFTER GIVING ACETAZOLAMIDE 500 MG AND FINDINGS ITS RELATION WITH POSTERIOR SEGMENT FINDINGS ASSESSED ON OPTICAL COHERENCE TOMOGRAPHY

BIOMETRIC ASSESSMENT OF OCULAR RIGIDITY AND ITS CORRELATION WITH POSTERIOR SEGMENT FINDINGS ASSESSED ON OPTICAL COHERENCE TOMOGRAPHY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041685
Enrollment
64
Registered
2022-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

Intervention1: Tab Acetazolamide-500mg: given Acetazolamide 500mg per oral stat in single sitting only Control Intervention1: Glaucoma and non glaucoma patients: Methods- After obtaining the informed

Sponsors

GMC HALDWANI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Glaucomatous patients and control subjects except under exclusion criteria

Exclusion criteria

Exclusion criteria: 1. Unclear ocular media 2. High myopia( >4 Dioptre) 3. High hyperopia( >4 Dioptre) 4. Patient having anterior segment pathology 5. Patient having any kind of posterior segment chorioretinal degeneration and chorioretinopathy 6. Any active infection in eye 7. Corneal scar 8. Nystagmus 9. Recent trauma to eye 10. Uveitis 11. Uncooperative Patients 12. Allergic to sulfa drugs 13. Age less than 15 14. Subjects with hepatic and renal disease

Design outcomes

Primary

MeasureTime frame
IOP, ACD, CCT & axial lengthTimepoint: taken at 0hr n post 2 hour after taking diamox in single visit of patient—

Secondary

MeasureTime frame
It can provide other alternative to control progression of glaucoma except IOPTimepoint: 1 Year—

Countries

India

Contacts

Public ContactDr Vimlesh sharma

GMC HALDWANI

drvimlesh.stm@gmail.com9897706633

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026